

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (Currently Amended) A ~~therapeutic agent composition for a~~ corneal epithelial ~~disorder~~ migration promoter comprising a compound having an effect of activating Rho as an active ingredient and a pharmacological carrier.

Claim 2. (Currently Amended) The ~~therapeutic agent composition for the~~ corneal epithelial ~~disorder~~ migration promoter as claimed in claim 1, wherein the compound having the effect of activating Rho is lysophosphatidic acid or an acyl derivative thereof.

Claim 3. (Currently Amended) The ~~therapeutic agent composition for the~~ corneal epithelial ~~disorder~~ migration promoter as claimed in claim 2, wherein said compound having the effect of activating Rho is oleyl lysophosphatidic acid.

Claims 4. to 7. (Cancelled)

Claim 8. (Currently Amended) A method of treating a corneal epithelial disorder comprising administering to a patient in need thereof a therapeutically effective amount of a ~~compound~~ corneal epithelial migration promoter having an effect of activating Rho.

Claim 9. (Currently Amended) The method as claimed in claim 8, wherein the ~~compound~~ corneal epithelial migration promoter having the effect of activating Rho is lysophosphatidic acid or an acyl derivative thereof[[,]] ~~wherein said acyl is a saturated or unsaturated higher aliphatic carbonyl or aromatic carbonyl.~~

Claim 10. (Currently Amended) The method as claimed in claim 9, wherein said ~~compound~~ corneal epithelial migration promoter having the effect of activating Rho is oleoyl lysophosphatidic acid.

Claim 11. (Previously Presented) The method as claimed in claim 8, wherein the corneal epithelial disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

Claim 12. (Previously Presented) The method as claimed in claim 9, wherein the corneal epithelial disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

Claim 13. (Previously Presented) The method as claimed in claim 10, wherein the corneal epithelial disorder is corneal ulcer, corneal erosion, keratitis or dry eye.

Claim 14. (Currently Amended) The method as claimed in claim 8, wherein the ~~compound~~ corneal epithelial migration promoter is administered in the form of eyedrops.

Claim 15. (Previously Presented) The method as claimed in claim 14, wherein the eyedrops are instilled once to several times a day in a concentration of 0.0001 to 1% (w/v) solution.

Claim 16. (Previously Presented) The method as claimed in claim 15, wherein the concentration is 0.001 to 1% (w/v) solution.

Claim 17. (Previously Presented) The method as claimed in claim 8, wherein the compound is orally administered in a daily dosage of 0.1 to 5000 mg.

Claim 18. (Previously Presented) The method as claimed in claim 17, wherein the daily dosage is 1 to 1000 mg.

Claim 19 (New) The method as claimed in claim 9, wherein said acyl is a saturated or unsaturated higher aliphatic carbonyl or aromatic carbonyl.